LASSO regression and WGCNA-based telomerase-associated lncRNA signaling predicts clear cell renal cell carcinoma prognosis and immunotherapy response.

Publisher: Impact Journals, LLC Country of Publication: United States NLM ID: 101508617 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1945-4589 (Electronic) Linking ISSN: 19454589 NLM ISO Abbreviation: Aging (Albany NY) Subsets: MEDLINE

Original Publication: Albany, NY : Impact Journals, LLC

Carcinoma, Renal Cell*/genetics ; Carcinoma, Renal Cell*/immunology ; Carcinoma, Renal Cell*/mortality ; Carcinoma, Renal Cell*/therapy ; Carcinoma, Renal Cell*/metabolism ; RNA, Long Noncoding*/genetics ; RNA, Long Noncoding*/metabolism ; Kidney Neoplasms*/genetics ; Kidney Neoplasms*/immunology ; Kidney Neoplasms*/mortality ; Kidney Neoplasms*/therapy ; Telomerase*/genetics ; Telomerase*/metabolism ; Immunotherapy*/methods; Humans ; Prognosis ; Gene Expression Regulation, Neoplastic ; Tumor Microenvironment/immunology ; Tumor Microenvironment/genetics ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Signal Transduction/genetics ; Male ; Female ; Gene Regulatory Networks

Objective: To investigate whether telomerase-associated lncRNA expression affects the prognosis and anti-tumor immunity of patients with renal clear cell carcinoma (ccRCC).
Methods: A series of analyses were performed to establish a prognostic risk model and validate its accuracy. Immune-related analyses were performed to assess further the association between immune status, tumor microenvironment, and prognostic risk models.
Results: Eight telomerase-associated lncRNAs associated with prognosis were identified and applied to establish a prognostic risk model. Overall survival was higher in the low-risk group.
Conclusion: The established prognostic risk model has a good predictive ability for the prognosis of ccRCC patients and provides a new possible therapeutic target for ccRCC.

Cancer Res. 2019 Sep 15;79(18):4557-4566. (PMID: 31350295)
Bosn J Basic Med Sci. 2022 Jun 01;22(3):435-452. (PMID: 34420511)
Cancer Med. 2019 Dec;8(17):7161-7173. (PMID: 31568700)
BMC Cancer. 2021 Apr 9;21(1):381. (PMID: 33836688)
Indian J Pathol Microbiol. 2022 Jul-Sep;65(3):598-603. (PMID: 35900487)
Brief Bioinform. 2021 Nov 5;22(6):. (PMID: 34260682)
J Hematol Oncol. 2020 Aug 10;13(1):110. (PMID: 32778143)
Genes (Basel). 2016 Jun 28;7(7):. (PMID: 27367732)
Imeta. 2023 Nov 16;2(4):e147. (PMID: 38868222)
Mech Ageing Dev. 2017 Oct;167:16-23. (PMID: 28888705)
N Engl J Med. 2019 Mar 21;380(12):1103-1115. (PMID: 30779531)
Mol Carcinog. 2019 Apr;58(4):544-553. (PMID: 30520148)
Dis Markers. 2022 Jul 8;2022:6402599. (PMID: 35845137)
J Natl Cancer Inst. 2018 Oct 1;110(10):1048-1058. (PMID: 30272225)
Cancers (Basel). 2022 Feb 05;14(3):. (PMID: 35159075)
Pathol Res Pract. 2020 Jun;216(6):152983. (PMID: 32327283)
CA Cancer J Clin. 2020 Mar;70(2):77. (PMID: 32101326)
Mol Carcinog. 2016 Oct;55(10):1458-66. (PMID: 26294352)
Nat Rev Genet. 2016 Jan;17(1):47-62. (PMID: 26666209)
Front Mol Biosci. 2021 Mar 04;8:567730. (PMID: 33748185)
Science. 1994 Dec 23;266(5193):2011-5. (PMID: 7605428)
J Cancer. 2020 Apr 27;11(14):4284-4296. (PMID: 32368311)
Endocr Relat Cancer. 2008 Dec;15(4):1069-74. (PMID: 18719091)
Aging (Albany NY). 2020 Jul 27;12(15):15359-15373. (PMID: 32716909)
Nat Rev Dis Primers. 2017 Mar 09;3:17009. (PMID: 28276433)
Front Oncol. 2021 Nov 05;11:755212. (PMID: 34804944)
Eur J Cancer. 1997 Apr;33(5):787-91. (PMID: 9282118)
Cell. 2015 Jan 15;160(1-2):48-61. (PMID: 25594174)
Urol Oncol. 2020 Aug;38(8):685.e1-685.e10. (PMID: 32409198)
Nat Rev Cancer. 2021 Jul;21(7):446-460. (PMID: 33953369)
J Immunother Cancer. 2020 Aug;8(2):. (PMID: 32817209)
Lab Invest. 2008 Feb;88(2):144-52. (PMID: 18158557)
Sci Rep. 2017 Jul 6;7(1):4748. (PMID: 28684781)
Prog Mol Biol Transl Sci. 2014;125:1-40. (PMID: 24993696)
Bioessays. 1990 Aug;12(8):363-9. (PMID: 2241933)
Front Oncol. 2020 Aug 20;10:1430. (PMID: 32974157)
Front Surg. 2022 Jul 21;9:860806. (PMID: 35937602)
Oncotarget. 2016 Sep 6;7(36):58696-58708. (PMID: 27509178)
J Clin Oncol. 2011 Apr 10;29(11):1415-23. (PMID: 21357789)
Front Genet. 2022 Apr 06;13:870945. (PMID: 35464855)
Front Genet. 2022 Oct 20;13:974726. (PMID: 36338996)
Cancers (Basel). 2020 Feb 28;12(3):. (PMID: 32121056)
Biochim Biophys Acta Rev Cancer. 2021 Apr;1875(2):188513. (PMID: 33493614)
Aging (Albany NY). 2020 Feb 22;12(4):3558-3573. (PMID: 32087603)
Front Immunol. 2022 Feb 22;13:843077. (PMID: 35273618)
Front Genet. 2022 Apr 13;13:871899. (PMID: 35495133)
Gene. 2012 May 1;498(2):135-46. (PMID: 22381618)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
J Exp Clin Cancer Res. 2020 May 6;39(1):78. (PMID: 32375866)
Trends Cancer. 2022 Aug;8(8):632-641. (PMID: 35568649)
J Mol Endocrinol. 2017 Feb;58(2):R129-R146. (PMID: 28057768)
Eur Urol. 2015 May;67(5):913-24. (PMID: 25616710)
Front Genet. 2023 Jan 23;14:1039813. (PMID: 36755568)
Biomark Med. 2020 Feb;14(3):223-238. (PMID: 31955607)
Science. 1997 Aug 15;277(5328):955-9. (PMID: 9252327)
Cancer Manag Res. 2020 Sep 15;12:8481-8490. (PMID: 32982441)
Sci Rep. 2016 Oct 11;6:35056. (PMID: 27725696)
Oncol Lett. 2020 Aug;20(2):1015-1027. (PMID: 32724340)
Cell. 2016 Jul 28;166(3):740-754. (PMID: 27397505)
Oncogene. 2021 Mar;40(9):1674-1689. (PMID: 33510354)

Keywords: immune infiltration; renal clear cell carcinoma; signature; telomerase genes (TRs)

0 (RNA, Long Noncoding)
EC 2.7.7.49 (Telomerase)
0 (Biomarkers, Tumor)

Date Created: 20240531 Date Completed: 20240621 Latest Revision: 20240703

20240703

PMC11210217

10.18632/aging.205871

38819232